You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Therapeutic Inhibition of BCL6 in Systemic Lupus Erythematosus

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAMS

    ABSTRACT Systemic autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus are characterized by polyclonal T cell activation driving the production of pathogenic class switched autoantibodiesThe class switchedsomatically mutated antibodies are generated from germinal centerGCB cellsA subset of effector CDT cellsknown as T follicular helperTfhcellshas been shown to play an ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this STTR is to identify novel small molecule compounds targeting the nitrogen respiration pathway of Pseudomonas aeruginosa This pathway is crucial to the pathogenesis of P aeruginosa in vivo but has not yet been exploited for antimicrobial drug discovery There is a clear need for new treatments to combat P aeruginosa infections Antibiotic re ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health

    SBC: SUPERGEN, INC.            Topic: N/A

    Description (provided by applicant): During systemic inflammatory response syndromes (SIRS), amplifying endogenous adenosine action by inhibiting adenosine deaminase (ADA) with 2-deoxycoformycin (pentostatin) reduces proinflammatory cytokine responses, limits tissue peroxidation, and has the potential to improve regional perfusion. Our long-term goal is to use pentostatin in the treatment of SIRS. ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy


    DESCRIPTION (provided by applicant): The overall goal of this Phase 2 STTR is to develop and commercialize a novel approach for allergen specific immunotherapy as a treatment for severe food allergy. Currently treatment to prevent severe food reactions isa major unmet need. There is no effective therapy, the only treatment being strict avoidance and emergency measures should an exposure occur. Th ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutics for inflammatory bowel disease from the microbiome

    SBC: SYMBIOTIX BIOTHERAPIES, INC.            Topic: 300

    PROJECT SUMMARY ABSTRACT Interactions between the gut microbiome and the immune system have been linked to inflammatory bowel disease IBD IBD is a chronic and progressive gastrointestinal disease characterized by uncontrolled activation of the intestinal immune system resulting in severe medical complications affecting over million patients in the United States It is a disease of high u ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Therapeutic Strategy for Recurrent Spontaneous Abortion

    SBC: Nora, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Recurrent spontaneous abortion (RSA) is a serious medical condition that affects approximately 1-3% of reproductive age women. At present, there is no FDA approved treatment for RSA. We hypothesize that failure to suppress Th1 cytokine production early in pregnancy is a major cause of RSA. We hypothesize that recombinant human granulocyte colony stimulating fa ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Therapeutic targeting of FKBP51 for the prevention of stress-induced preterm birth

    SBC: DARE BIOSCIENCE, INC.            Topic: NICHD

    In the United States, one in ten babies is born prematurely. The earlier in pregnancy a baby is born, the more likely they will have an extended hospital stay, as well as serious health complications such as respiratory distress syndrome, necrotizing enterocolitis, deafness, vision problems and cerebral palsy. Maternal stress is a well-established risk factor for preterm birth, and recent studies ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic Utility of renalase and renalase peptides in cisplatin-mediated renal

    SBC: BESSOR PHARMA, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Cisplatin is a cornerstone therapy for a number of cancers including testicular, bladder, ovarian and lung. It is also used to treat cancers in children. In all cases there is a high incidence of acute kidney injury (AKI) that can also lead to later stage kidney damage. This risk limits its use. We have found in pilot studies that renalase, or peptide fragment ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health

    SBC: MANDALMED, INC.            Topic: N/A


    STTR Phase I 1999 Department of Health and Human Services
  10. Thermostable Inactivated Potent Yellow Fever Vaccine


    SummaryYellow Fever (YF) is an acute viral hemorrhagic fever disease caused by Yellow Fevervirus (YFV) and an estimated 200,000 YF infections occur annually. Approximately 50% ofinfected individuals that develop a severe case of the disease will die. The infection iscommon in Africa and South America, and travelers and residents of those areas are athigh risk of contracting the virus. A recent res ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government